HCV viral breakthrough is an ongoing possibility during the pegylated interferon/ribavirin continuation phase after triple therapy with telaprevir (Incivek or Incivek or Incivo), especially for difficult-to-treat patients, researchers reported this week at the Digestive Disease Week conference (DDW 2013) in Orlando.
Treating herpes simplex virus type 2 (HSV-2) with valacyclovir (Valtrex) was associated with a substantial reduction in plasma hepatitis C virus levels in dually-infected individuals, according to a small study presented at the Digestive Disease Week conference (DDW 2013)this week in Orlando.
- Category: HBV Treatment
- Published on Wednesday, 22 May 2013 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 2013 Digestive Disease Week annual meeting (DDW 2013) in Orlando, Florida, May 18-21, 2013.
Conference highlights include direct-acting hepatitis C drugs, new strategies for using approved HCV protease inhibitors and interferon/ribavirin, and interferon-free regimens.
Adding the HCV protease inhibitor simeprevir (formerly TMC435) to pegylated interferon and ribavirin cured 79% of prior relapsers, and most were eligible to complete treatment after 3 months, according to findings from the PROMISE study presented at the Digestive Disease Week meeting (DDW 2013) this week in Orlando.
- Category: HCV Treatment
- Published on Wednesday, 15 May 2013 00:00
- Written by Janssen
On May 13, Janssen announced that its application for approval of the next-generation hepatitis C virus NS3/4A protease inhibitor simeprevir (formerly TMC435) has received priority review status from the U.S. Food and Drug Administration (FDA), giving it an estimated timeline of 6 months.